Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.

Al Yami MS, Alfayez OM, Alsheikh R

Heart, lung & circulation29 Mar 2018Cited by 2 (Europe PMC)

PMID29887418DOI10.1016/j.hlc.2018.03.018PepBankPUB-29887418

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists reduced death from cardiovascular causes by 13% versus placebo.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group lowered the risk of death from heart and blood vessel causes more than placebo.
Peptide
Liraglutide
Outcome
DecreaseDeath from cardiovascular causes
Study
n = 33,457
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Risk ratio
0.87 RR
CV death, 95% CI 0.78-0.96
Source sentences
Summary
a 13% reduction in death from cardiovascular causes in patients who received GLP-1 agonists versus placebo (RR 0.87, 95% CI: 0.78-0.96)
1 context sentence(design, population, supporting numbers)
Summary · context
All included trials were large CV outcome trials of GLP-1 agonists versus placebo in T2DM.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2988741801
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not significantly reduce non-fatal myocardial infarction versus placebo.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group did not significantly lower non-fatal heart attacks compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeNon-fatal myocardial infarction
Study
n = 33,457
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Risk ratio
0.95 RR
Non-fatal MI, 95% CI 0.86-1.04
Source sentences
Summary
no statistically significant reduction was observed with GLP-1 agonists in terms of reducing non-fatal MI (RR 0.95, 95% CI: 0.86-1.04)
1 context sentence(design, population, supporting numbers)
Summary · context
All included trials were large CV outcome trials of GLP-1 agonists versus placebo in T2DM.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2988741802
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not significantly reduce non-fatal stroke versus placebo.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group did not significantly lower non-fatal strokes compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeNon-fatal stroke
Study
n = 33,457
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Risk ratio
0.89 RR
Non-fatal stroke, 95% CI 0.76-1.03
Source sentences
Summary
non-fatal stroke events (RR 0.89, 95% CI: 0.76-1.03)
1 context sentence(design, population, supporting numbers)
Summary · context
All included trials were large CV outcome trials of GLP-1 agonists versus placebo in T2DM.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2988741803
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists did not significantly reduce heart failure hospitalisation versus placebo.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group did not significantly lower hospital stays for heart failure compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeHospitalisation for heart failure
Study
n = 33,457
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Risk ratio
0.94 RR
HF hospitalisation, 95% CI 0.84-1.04
Source sentences
Summary
rates of HF hospitalisation (RR 0.94, 95% CI: 0.84-1.04)
1 context sentence(design, population, supporting numbers)
Summary · context
All included trials were large CV outcome trials of GLP-1 agonists versus placebo in T2DM.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2988741804
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, the network meta-analysis showed no significant differences among the GLP-1 receptor agonist interventions.
In plain wordsIn adults with type 2 diabetes, the network analysis found no significant differences between the GLP-1 drugs compared.
Peptide
Liraglutide
Outcome
No significant changeCardiovascular outcomes in network meta-analysis across interventions
Study
n = 33,457
Comparator
Other GLP-1 receptor agonists
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
The network meta-analysis (NMA) showed no significant differences among all the interventions.
1 context sentence(design, population, supporting numbers)
Summary · context
All included trials were large CV outcome trials of GLP-1 agonists versus placebo in T2DM.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2988741805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.